PURPOSE: Left atrial (LA) remodeling associated with atrial fibrillation (AF) is known to be related to inflammation and collagen turnover. We investigated the changes in the biomarkers of inflammation and collagen turnover in relation to LA reverse remodeling during the 1st year after AF ablation. METHODS: Biomarkers of inflammation [high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6)] and collagen turnover [matrix metalloproteinase-2 (MMP-2), tissue inhibitor of MMP-2 (TIMP-2), transforming growth factor beta 1 (TGF-β1)], as well as asymmetric dimethylarginine (ADMA) and adiponectin levels were measured, and echocardiographic measurements were obtained before and 3, 6, and 12 months after ablation in 60 AF patients (49 males; age, 57.6 ± 10.9 years). RESULTS: During a 12.1 (11.5-12.9)-month follow-up period, AF recurred in 29 patients (48 %). Neither the LA volume (LAV) nor the left ventricular ejection fraction (LVEF) changed significantly during the 1st year in this group, but the LAV decreased significantly, and the LVEF increased significantly in the nonrecurrence group. The hs-CRP and IL-6 decreased after ablation but returned near to baseline levels in both groups by 12 months. The MMP-2 remained increased during the 1st year in both groups, whereas the TIMP-2 increased markedly in the nonrecurrence group but did not change substantially in the recurrence group. The TGF-β1 increased in both groups, but the change was less pronounced in the recurrence group. The ADMA and adiponectin levels did not change substantially in either group. CONCLUSIONS: Despite reverse remodeling, the inflammation and collagen turnover biomarker levels are quite progressive during the 1st year after ablation and may explain the late AF recurrence.
PURPOSE: Left atrial (LA) remodeling associated with atrial fibrillation (AF) is known to be related to inflammation and collagen turnover. We investigated the changes in the biomarkers of inflammation and collagen turnover in relation to LA reverse remodeling during the 1st year after AF ablation. METHODS: Biomarkers of inflammation [high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6)] and collagen turnover [matrix metalloproteinase-2 (MMP-2), tissue inhibitor of MMP-2 (TIMP-2), transforming growth factor beta 1 (TGF-β1)], as well as asymmetric dimethylarginine (ADMA) and adiponectin levels were measured, and echocardiographic measurements were obtained before and 3, 6, and 12 months after ablation in 60 AFpatients (49 males; age, 57.6 ± 10.9 years). RESULTS: During a 12.1 (11.5-12.9)-month follow-up period, AF recurred in 29 patients (48 %). Neither the LA volume (LAV) nor the left ventricular ejection fraction (LVEF) changed significantly during the 1st year in this group, but the LAV decreased significantly, and the LVEF increased significantly in the nonrecurrence group. The hs-CRP and IL-6 decreased after ablation but returned near to baseline levels in both groups by 12 months. The MMP-2 remained increased during the 1st year in both groups, whereas the TIMP-2 increased markedly in the nonrecurrence group but did not change substantially in the recurrence group. The TGF-β1 increased in both groups, but the change was less pronounced in the recurrence group. The ADMA and adiponectin levels did not change substantially in either group. CONCLUSIONS: Despite reverse remodeling, the inflammation and collagen turnover biomarker levels are quite progressive during the 1st year after ablation and may explain the late AF recurrence.
Authors: Norbert Stefan; Barbora Vozarova; Tohru Funahashi; Yuji Matsuzawa; Christian Weyer; Robert S Lindsay; Jack F Youngren; Peter J Havel; Richard E Pratley; Clifton Bogardus; P Antonio Tataranni Journal: Diabetes Date: 2002-06 Impact factor: 9.461
Authors: Jens J Kaden; Carl-Erik Dempfle; Tim Sueselbeck; Martina Brueckmann; Tudor C Poerner; Dariusch Haghi; Karl K Haase; Martin Borggrefe Journal: Cardiology Date: 2003 Impact factor: 1.869
Authors: John H Rosenberg; John H Werner; Gilman D Plitt; Victoria V Noble; Jordan T Spring; Brooke A Stephens; Aleem Siddique; Helenmari L Merritt-Genore; Michael J Moulton; Devendra K Agrawal Journal: Expert Rev Cardiovasc Ther Date: 2018-12-29
Authors: D Mastronicola; E Arcuri; M Arese; A Bacchi; S Mercadante; P Cardelli; G Citro; P Sarti Journal: Cell Mol Life Sci Date: 2004-12 Impact factor: 9.261
Authors: Pavel Osmancik; Štěpán Havránek; Veronika Bulková; Jan Chovančík; Tomáš Roubíček; Dalibor Heřman; Zuzana Čarná; Vladimír Tuka; Martin Matoulek; Martin Fiala; Otakar Jiravský; Sylvie Stregl-Hruskova; Adam Latiňák; Jiřina Kotryová; Jiří Jarkovský Journal: BMJ Open Date: 2022-06-15 Impact factor: 3.006
Authors: Allan Bohm; Lubos Urban; Lubomira Tothova; Ljuba Bacharova; Peter Musil; Jan Kyselovic; Peter Michalek; Tomas Uher; Branislav Bezak; Peter Olejnik; Robert Hatala Journal: J Interv Card Electrophysiol Date: 2021-03-10 Impact factor: 1.900